Trial · NCT06588738
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | To determine whether ESK-001 reduces the severity of psoriasis by 75% (using the PASI) or by at least 2 points (using sPGA score) compared to placebo | 16 weeks | Proportion of patients achieving ≥75% reduction in PASI score. Proportion of patients achieving a score of 0 or 1 on sPGA. |
| Secondary | To compare the Psoriasis Area and Severity Index (PASI-90 and PASI-100) between ESK-001 and placebo or apremilast | 24 weeks | Proportion of patients achieving of ≥90% or 100% reduction in PASI |
| Secondary | To compare the Psoriasis Area and Severity Index (PASI-75) between ESK-001 and apremilast | 24 weeks | Proportion of patients achieving of ≥75% reduction in PASI |
| Secondary | To compare the Static Physician's Global Assessment (sPGA-0/1) between ESK-001 and apremilast | 24 weeks | Proportion of patients achieving a score of 0 or 1 on sPGA |
| Secondary | To compare the affected body surface area (%BSA) between ESK-001 and placebo or apremilast | 24 weeks | Change from baseline in %BSA |
| Secondary | To compare the scalp specific Physician's Global Assessment (ssPGA) between ESK-001 and placebo or apremilast | 24 weeks | Proportion of patients achieving a score of 0 or 1 on ssPGA |
| Secondary | To compare the Psoriasis Symptoms and Signs Diary (PSSD) between ESK-001 and placebo or apremilast | 24 weeks | Proportion of patients achieving a score of 0 |
| Secondary | To compare the Dermatology Life Quality Index (DLQI) between ESK-001 and placebo or apremilast | 24 weeks | Proportion of patients achieving a score of 0 or 1 |
| Secondary | To compare the Pruritus numeric rating scale (NRS) between ESK-001 and placebo | 24 weeks | Change from baseline in Pruritus NRS (scale is from 0 (no pain) to 10 (severe pain)). |
| Secondary | Proportion of patients with treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) | 24 weeks | Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) |
| Secondary | To characterize the pharmacokinetics of ESK-001 | 24 weeks | Maximum \[Cmax\] and minimum \[Cmin\] plasma concentration |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06588738/registered